Summit Therapeutics Inc. Increase (Decrease) in Employee Related Liabilities
Summit Therapeutics Inc. (SMMT) reported Increase (Decrease) in Employee Related Liabilities of -$5.48 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2026-07-23
- Summit Therapeutics Inc. increase (decrease) in employee related liabilities for the quarter ending 2026-06-30 was $2.37M, a 8.67% increase year-over-year.
- Summit Therapeutics Inc. increase (decrease) in employee related liabilities for the quarter ending 2026-03-31 was -$7.85M.
- Summit Therapeutics Inc. increase (decrease) in employee related liabilities for the quarter ending 2025-12-31 was $3.96M, a 2.13% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in employee related liabilities for the quarter ending 2025-09-30 was $4.36M, a 42.20% increase year-over-year.
- Summit Therapeutics Inc. increase (decrease) in employee related liabilities for fiscal 2025 was $2.91M, a 55.64% decline from fiscal 2024.
- Summit Therapeutics Inc. increase (decrease) in employee related liabilities for fiscal 2024 was $6.56M.
- Summit Therapeutics Inc. increase (decrease) in employee related liabilities for fiscal 2023 was -$235.00K, a 114.61% decline from fiscal 2022.
- Summit Therapeutics Inc. increase (decrease) in employee related liabilities for fiscal 2022 was $1.61M, a 48.99% decline from fiscal 2021.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | -$5.48M 10-Q · filed 2026-07-23 | -$1.53M derived: sum of 3 quarters · filed 2026-07-23 | $2.83M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | -$7.85M 10-Q · filed 2026-04-30 | -$3.90M derived: sum of 2 quarters · filed 2026-04-30 | $464.00K derived: sum of 3 quarters · filed 2026-04-30 | $2.65M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $8.32M derived: sum of 2 quarters · filed 2026-02-23 | $10.50M derived: sum of 3 quarters · filed 2026-07-23 | $2.91M 10-K · filed 2026-02-23 |
| 2025-09-30 | $4.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $6.54M derived: sum of 2 quarters · filed 2026-07-23 | -$1.05M 10-Q · filed 2025-10-20 | $3.00M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $2.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | -$5.41M 10-Q · filed 2026-07-23 | -$1.36M derived: sum of 3 quarters · filed 2026-07-23 | $1.70M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | -$7.59M 10-Q · filed 2026-04-30 | -$3.55M derived: sum of 2 quarters · filed 2026-04-30 | -$480.00K derived: sum of 3 quarters · filed 2026-04-30 | -$1.64M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $7.11M derived: sum of 2 quarters · filed 2026-02-23 | $5.95M derived: sum of 3 quarters · filed 2026-02-23 | $6.56M 10-K · filed 2026-02-23 |
| 2024-09-30 | $3.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $1.91M derived: sum of 2 quarters · filed 2025-10-20 | $2.52M 10-Q · filed 2025-10-20 | $4.42M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$551.00K 10-Q · filed 2025-08-11 | $1.36M derived: sum of 3 quarters · filed 2026-02-23 | $1.35M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $606.00K 10-Q · filed 2025-05-01 | $2.52M derived: sum of 2 quarters · filed 2026-02-23 | $2.51M derived: sum of 3 quarters · filed 2026-02-23 | $3.61M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.90M derived: sum of 2 quarters · filed 2026-02-23 | $3.00M derived: sum of 3 quarters · filed 2026-02-23 | -$235.00K 10-K · filed 2026-02-23 |
| 2023-09-30 | -$10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $1.09M derived: sum of 2 quarters · filed 2024-10-30 | -$2.15M 10-Q · filed 2024-10-30 | $1.90M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$2.13M 10-Q · filed 2024-08-06 | $1.91M derived: sum of 3 quarters · filed 2025-02-24 | $2.56M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-03-31 | -$3.24M 10-Q · filed 2024-05-01 | $808.00K derived: sum of 2 quarters · filed 2025-02-24 | $1.46M derived: sum of 3 quarters · filed 2025-02-24 | $1.89M derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-12-31 | $4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $4.69M derived: sum of 2 quarters · filed 2025-02-24 | $5.13M derived: sum of 3 quarters · filed 2025-02-24 | $1.61M 10-K · filed 2025-02-24 |
| 2022-09-30 | $648.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.09M derived: sum of 2 quarters · filed 2023-11-07 | -$2.44M 10-Q · filed 2023-11-07 | -$381.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $438.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$3.08M 10-Q · filed 2023-08-09 | -$1.03M derived: sum of 3 quarters · filed 2023-08-09 | $522.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$3.52M 10-Q · filed 2023-05-11 | -$1.47M derived: sum of 2 quarters · filed 2023-05-11 | $84.00K derived: sum of 3 quarters · filed 2023-05-11 | -$510.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $3.61M derived: sum of 2 quarters · filed 2023-03-09 | $3.01M derived: sum of 3 quarters · filed 2023-03-09 | $3.15M 10-K · filed 2023-03-09 |
| 2021-09-30 | $1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $957.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.10M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$594.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$453.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $141.00K 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |